To acquire money through an initial public offering, Mankind Pharma has submitted its drafts red herring prospectus (DRHP) papers to market regulator Securities and Exchange Board of India (SEBI) (IPO).
The promoters of the company and currentshareholders will offer for sale (OFS) 4 crores (40,058,844) equity shares as part of the IPO. The company is backed by Ramesh Juneja, Rajeev Juneja, Sheetal Arora, Prem Sheetal Family Trust, and Ramesh Juneja Family Trust.
The projected size of the IPO is around 5,500 crores, which could make it one of the biggest public offerings by a domestic pharmaceutical company ever.
Mankind Pharma, a 1991 incorporation, is one of India’s top pharmaceutical firms. The company’s well-known products in addition to branded generic medications include Prega-News pregnancy testing kits, Manforce condoms, Gas-O-Fast ayurvedic antacids, and acne medication AcneStar, Unwanted-21, Ringout anti-fungal powder, Kaloree 1 artificial sweetener, Heal-O-Kind anti-bacterial ointment, Addiction Deodorant, and KabzEnd are some of the products available.
MAIN AREA OF THE COMPANY
It focuses on the gynaecological, orthopaedic, anti-allergic, anti-fungal, gastrointestinal, cardiovascular, and antibiotic segments.Amlokind and Telmikind, two hypertension medications; Cefakind and Moxikind-CV, two antibiotic medications; Nurokind, a vitamin; Rabekind, an ulcer medication; and Zenflox, an antibacterial medication; are among the most popular prescription medications available.
It had 23 production facilities operating as of March 31, 2022, including ones in Himachal Pradesh, Sikkim, Rajasthan, Andhra Pradesh, and Uttarakhand.
FINANCIALS OF THE COMPANY
For the fiscal years 2020, 2021, and 2022, the company’s revenue from operations in India was 5,788.8 crores, 6,028 crores, and 7,594.7 crores, representing 98.70%, 97.01%, and 97.60% of its total revenue from operations, respectively. It has a lot of cash and has been trying to expand its OTC product vertical for better margins, so there’s a lot of consumer appeal. The firm posted revenue of about Rs 8,000 crore and EBITDA of Rs 2,200 crore in FY22. I am also putting some images which is taken from mankind Pharma website So, that you can clear idea about their financials.
Its major markets after India are the United States, Bangladesh, Sri Lanka, and Nepal.
Capital International paid $200 million for an 11% stake in Mankind from ChrysCapital in 2015.
ChrysCapital purchased a 10% stake in the company again in April 2018 for approximately $350 million.
Mankind Pharma announced the launch ofMankind Agritech Pvt Ltd in April this yea to foray into the agritech segment, and the company said it will invest 200 crores in the next two to three years.
